Cagrilintide

Summary

Cagrilintide is a long-acting synthetic version of amylin, a hormone your pancreas releases alongside insulin that signals fullness and slows how fast the stomach empties. That makes it a genuinely different lever from the GLP-1 drugs: semaglutide and tirzepatide act on GLP-1 (and, for tirzepatide, GIP) receptors, while cagrilintide works through the amylin pathway. The interesting question was always whether combining the two would add up, and the Phase 3 answer is that it does. CagriSema — cagrilintide 2.4 mg plus semaglutide 2.4 mg, injected once weekly — produced roughly 20% average body-weight reduction over 68 weeks in a 3,417-person trial, ahead of either component alone. The detail that gets lost in the headlines is the monotherapy arm: cagrilintide by itself produced less weight loss than semaglutide by itself. It is a strong combination partner, not a stronger replacement. None of it is approved yet.

What people use it for

Almost entirely weight loss, and in practice almost entirely as the combination with semaglutide rather than on its own. In the obesity-drug conversation it is discussed as the next entrant after semaglutide and tirzepatide, and as evidence that stacking mechanisms — amylin plus GLP-1 — may push weight loss past what a single pathway achieves. A second line of research covers type 2 diabetes, where the combination was tested for blood-sugar control as well as weight. Because it is investigational, there is no legitimate route to it outside a trial; what circulates online under the name is a separate matter, covered under regulatory status below.

Human evidence

REDEFINE 1 (the pivotal obesity trial). A 68-week Phase 3 trial randomized 3,417 adults with obesity, or overweight plus at least one weight-related condition, and without type 2 diabetes. Published in the New England Journal of Medicine in 2025, it met its primary endpoint. Average weight reduction at week 68 was about 20.4% on the combination, against 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3% for placebo. Accounting for full treatment adherence, the combination figure rises to 22.7%. Roughly 60% of participants lost at least 20% of body weight, and 23% lost 30% or more — figures at the top of what obesity pharmacotherapy has achieved.

Two things follow from that table, and only one of them is in the marketing. The combination is clearly the best-performing arm, which earns the combination claim an S+. But cagrilintide on its own came in below semaglutide on its own — so the amylin analog is not a more powerful drug than the GLP-1 it is paired with; its value is additive. The monotherapy claim rests on that single trial arm, so it grades S.

REDEFINE 2 (type 2 diabetes). A companion Phase 3 trial tested the combination in adults with overweight or obesity and type 2 diabetes, also published in NEJM in 2025, reporting an HbA1c reduction of about 1.91%. That is a real result in a well-powered trial, but it is one trial in this population, so the diabetes claim grades S rather than S+.

How it compares to tirzepatide. There is no published head-to-head trial. A network meta-analysis — an indirect comparison assembled from separate trials — put tirzepatide 15 mg marginally ahead at −17.97% against CagriSema at −17.84%, a gap small enough to be inside the noise of that method. Anyone claiming a clear winner between the two is reading more into indirect comparison than it supports.

Still outstanding. The cardiovascular-outcomes trial (REDEFINE 3, NCT05669755) is ongoing. Until it reports, there is no evidence that cagrilintide reduces heart attacks or strokes — the claim semaglutide earned only after its own dedicated outcomes trial.

Animal / preclinical evidence

Amylin biology is well characterized and long predates this molecule: amylin is co-secreted with insulin, acts on receptors in the hindbrain, and reduces food intake by promoting satiety and slowing gastric emptying. Pramlintide, a short-acting amylin analog, has been an approved diabetes drug for years, which establishes the pathway is druggable in humans. Cagrilintide's engineering goal was duration — modifications that stretch the half-life enough for once-weekly dosing. The preclinical work supports the mechanism, but note that this brief's grades rest on the human trials, not on the animal data, because for once the human data is the stronger evidence.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Because cagrilintide is trial-only, there is no legitimate user population, and community discussion largely concerns material bought online under the name — which cannot be assumed to be the trial compound, or to contain what the label says, or to be sterile. Reports of appetite suppression and nausea are consistent with amylin pharmacology, but uncontrolled reports about an unverified substance carry essentially no evidentiary weight. Anyone reasoning from these is reasoning about an unknown.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

REDEFINE 1 used cagrilintide 2.4 mg with semaglutide 2.4 mg, once weekly by subcutaneous injection, for 68 weeks, with doses escalated during the trial — 57.3% of the combination group were on the highest dose by week 68. The monotherapy arm used cagrilintide 2.4 mg once weekly on the same schedule. These figures describe what was given to enrolled participants under clinical supervision, with screening, monitoring and a known product. They do not transfer to material of unverified identity or concentration, and they are not a protocol.

Safety & side effects

The adverse-event profile in REDEFINE 1 was predominantly gastrointestinal — nausea, vomiting, and related effects — and the large majority were mild to moderate and diminished over time. That pattern is consistent with the GLP-1 class and with amylin pharmacology, both of which slow gastric emptying. Tolerability shaped dosing: only 57.3% of the combination group were on the highest dose at week 68, against 82.5% for cagrilintide alone, which suggests the combination is harder to tolerate at full dose than the amylin analog by itself. Longer-term safety, and any cardiovascular safety signal, await the ongoing outcomes trial. Separately, and more importantly for anyone reading this outside a trial: none of this safety data applies to unregulated product bought online, where identity, purity, and sterility are all unknown.

Regulatory / legal status

Cagrilintide is investigational. It is not FDA-approved alone or as CagriSema, is not available by prescription, and can be obtained legitimately only through a clinical trial. Its Phase 3 program has reported in obesity (REDEFINE 1) and type 2 diabetes (REDEFINE 2), with a cardiovascular-outcomes trial ongoing (REDEFINE 3). Material sold online under the names "cagrilintide" or "CagriSema" is not the trial product and has been through no regulatory review whatsoever — which is why the claim that it is a proven, available obesity medicine grades C. Regulatory status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

Cagrilintide entered the mainstream obesity-drug conversation through the CagriSema headlines, usually framed as the next step past Ozempic and Mounjaro. The 20%-plus weight-loss figure is real and comes from a large, published, placebo-controlled Phase 3 trial. Two things are routinely dropped: cagrilintide on its own underperformed semaglutide on its own, so the story is about combination rather than a stronger single drug; and the tirzepatide comparison people reach for is an indirect network meta-analysis, not a head-to-head trial, with a difference too small to declare a winner.